Bharat Book

Global Therapeutic Report on Erythropoietin Stimulating Agents [2015]

Press Release   •   Dec 24, 2015 13:52 IST

Dec 24 2015 Mumbai, India: announces a report on “Global Therapeutic Report on Erythropoietin Stimulating Agents [2015] ”. The market for erythropoietin in Asia-Pacific and South America is expected to grow at the fastest rate compared to other global markets, which are expected to decline.

The global market for erythropoietin stimulating agents with a compound annual growth rate (CAGR) of 0.2% for the period 2015-2020.

This report provides:

-An overview of the global markets and therapeutic applications for erythropoietin stimulating agents (ESAs).

-Analyses of U.S. as well as international market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.

-Coverage of the market in value terms broken down by major types of erythropoietin, by major regions, and by applications.

-Coverage of applications including cancer therapy, chronic kidney disease (CKD) therapy, HIV therapy, and anemia therapy.

-Major trends and challenges affecting the market and the supplier landscape.

-A look at industrial developments and the advent of biosimilars impacting the market.

-Analysis of the risks associated with the market for abusive uses of ESAa and their adverse effects.

-Profiles of major players in the industry.


The global market for erythropoietin drug can be broadly classified into two segments: biologics and biosimilars.

The major types of biologic erythropoietin drugs based on different biological properties are epoetin-alfa, epoetin-beta, darbepoetin-alfa and epoetin-theta.

The major types of biosimilar erythropoietin drug based on the different biological properties are epoetin-zeta, epoetin-omega, epoetin-lambda and epoetin-delta.

The global erythropoietin biologics drug market has been growing in terms of value from the past 15 years in pace with the increasing prevalence of chronic kidney diseases throughout the world, however the market is expected to see decline in the forecast period due to expiry of major patented drugs in the U.S. and European markets; and due to the entrant of many biosimilar erythropoietin drug in the European market since 2008 which are approximately 20% to 30% cheaper compared to patented drug.

The global erythropoietin biosimilars drug market has been growing rapidly in the last decade years, primarily due to the patent expiry of major erythropoietin biologic drug in European market and demand for cheaper priced erythropoietin drugs in the Asia-Pacific, South America, Middle-east and African market. The study covered in this report has been conducted to analyze and quantify the emerging market opportunities for erythropoietin drug, as well as to highlight the key current research efforts that are driving erythropoietin drug into new applications. In addition, major players of the erythropoietin drug, along with their upcoming and anticipated erythropoietin-related products are analyzed to demonstrate how these advances might impact global erythropoietin drug market.

The application of erythropoietin drug is divided broadly into three types: chronic kidney diseases; oncology diseases; and other applications such as treatment of anemia in HIV patients. The key drivers for the erythropoietin drug market are increasing case of chronic disease and increasing prevalence of cancer.

Amgen Inc., Hoffmann-La Roche and Johnson & Johnson are some of the key players of biologics erythropoietin drug market. Sandoz (subsidiary of Novartis International AG), Hospira (subsidiary of Pfizer Inc.), 3SBio, BioSidus and Teva Pharmaceutical Industries Ltd. are some of the major players of biosimilar erythropoietin drugs market.

The market for erythropoietin in Asia-Pacific and South America is expected to grow at the fastest rate compared to other global markets, which are expected to decline. The entrant of erythropoietin biosimilars drugs in Europe and the U.S. will create a huge impact during the forecast period, resulting in a decline in the global erythropoietin drug market.

This report also highlights the supplier landscape with a focus on major companies, with detailed profiles given.


The goal of this report is to provide an up-to-date analysis of recent developments and current trends in the global erythropoietin drug market. The objective of this type of systematic research is to quantify the projected impact of both internal and external forces that are affecting the global erythropoietin drug market today and that will affect the industry for the next several years. Factors involved in driving product demand within this vast untapped market will be explored in conjunction with trends, potential sales and forecasts for various market sectors. In addition, major players closely involved in the production of these erythropoietin drugs, as well as their upcoming and anticipated products resulting from further research and development will be analyzed to demonstrate how these advances might influence the existing erythropoietin drugs market.


Increasing cases of chronic kidney diseases, oncology diseases; and anemia in HIV patients across regions and the expiry of Epogen’s patent in 2015, and upcoming patent expiry of Aranesp in Europe is expected to increase the demand for the global erythropoietin biosimilar drug market.


The scope of this report is broad and covers erythropoietin drug used globally in various types of applications. The market is broken down in terms of the various types of erythropoietin drug by region and by applications. Revenue forecasts from 2015 to 2020 are given for erythropoietin drug, with its applications and regional markets.

The report also includes a discussion of the major players in each of the regional markets for erythropoietin drug. It explains the major market drivers of the global erythropoietin drug industry, the current trends within the industry, major industry challenges and the regional dynamics of the global erythropoietin drug market. The report concludes with a special focus on the supplier landscape. It includes detailed profiles of the major vendors in the erythropoietin drug industry globally.


This report is intended especially for developers, as well as consumers with a vital interest in erythropoietin drug and its application. In addition, because of this report’s business focus, it will be useful to sales executives and business managers as an up-to-date guide that includes challenges, drivers and trends that are expected to be significant factors in the current and future markets.

The report should also be of interest to those in industries such as erythropoietin drug raw materials (manufacturers and suppliers), healthcare consulting companies, laboratory equipment manufacturers and pharmaceutical manufacturers.


The findings and conclusions of this report are based on information gathered from a variety of primary and secondary sources. Sources of information included industry association data and interviews conducted with erythropoietin drug companies. In addition, other secondary sources were consulted for the report, such as the Internet, industry journals and publications, product literature, white papers and technical journals, and financial reports from industry suppliers.

The base year for analysis and projection is 2014. With 2014 as a baseline, market projections were developed for 2015 to 2020. These projections are based on a consensus among the primary contacts, combined with our understanding of the key market drivers and their impact from historical and analytical perspectives. The analytical methodologies used to generate the market estimates are described in detail in the market analyses. All dollar projections presented in this report are in 2014 constant U.S. dollars.


A descriptive study has been done for the global market for erythropoietin drug, based on a quantitative and qualitative approach.

The Report collects data through a variety of primary and secondary sources including, but not limited to, interviews with industry vendors, white papers, business journals, public financial proceedings and historical market data from the Internet. The market data are assessed and validated considering interrelated market attributes and the impact of global economic variables.

Next, market for each erythropoietin drug is obtained using a bottom-up approach through extensive research by region and application of these drugs. Finally, the global market is obtained by adding all the erythropoietin drugs by region and application.

For more information kindly visit :

Related Reports :

About Bharat Book Bureau :

Bharat Book Bureau is the leading market research information provider for market research reports, company profiles, industry analysis, country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don’t match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.


Contact us at :

Bharat Book Bureau

Tel: +91 22 27810772 / 27810773



Follow us on Twitter:

Follow us on Linked In :

Our Blog :

Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.